CoChat

Impact of apolipoprotein ɛ4–cerebrospinal fluid beta‐amyloid interaction on hippocampal volume loss over 1 year in mild cognitive impairment

Open access
Chiang, Gloria C., Insel, Philip S., Tosun, Duygu, Schuff, Norbert, Truran‐Sacrey, Diana, Raptentsetsang, Sky T., Thompson, Paul M., Reiman, Eric M., Jack, Clifford R., Fox, Nick C., Jagust, William J., Harvey, Danielle J., Beckett, Laurel A., Gamst, Anthony, Aisen, Paul S., Petersen, Ron C., Weiner, Michael W. · 2011 · Alzheimer's & Dementia
Cited by 31

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Abstract

Background: The majority of studies relating amyloid pathology with brain volumes have been cross‐sectional. Apolipoprotein ɛ4 (APOE ɛ4), a genetic risk factor for Alzheimer's disease, is also known to be associated with hippocampal volume loss. No studies have considered the effects of amyloid pathology and APOE ɛ4 together on longitudinal volume loss. Methods: We evaluated whether an abnormal level of cerebrospinal fluid beta‐amyloid (CSF Aβ) and APOE ɛ4 carrier status were independently associated with greater hippocampal volume loss over 1 year. We then assessed whether APOE ɛ4 status and CSF Aβ acted synergistically, testing the significance of an interaction term in the regression analysis. We included 297 participants: 77 cognitively normal, 144 with mild cognitive impairment (MCI), and 76 with Alzheimer's disease. Results: An abnormal CSF Aβ level was found to be associated with greater hippocampal volume loss over 1 year in each group. APOE ɛ4 was associated with hippocampal volume loss only in the cognitively normal and MCI groups. APOE ɛ4 carriers with abnormal CSF Aβ in the MCI group acted synergistically to produce disproportionately greater volume loss than noncarriers. Conclusion: Baseline CSF Aβ predicts progression of hippocampal volume loss. APOE ɛ4 carrier status amplifies the degree of neurodegeneration in MCI. Understanding the effect of interactions between genetic risk and amyloid pathology will be important in clinical trials and our understanding of the disease process.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jalz.2010.12.010

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Cited by

See all 31

Metadata

Authors
Chiang, G. C., Insel, P. S., Tosun, D., Schuff, N., Truran‐Sacrey, D., Raptentsetsang, S. T., Thompson, P. M., Reiman, E. M., Jack, C. R., Fox, N. C., Jagust, W. J., Harvey, D. J., Beckett, L. A., Gamst, A., Aisen, P. S., Petersen, R. C., & Weiner, M. W.
Venue
Alzheimer's & Dementia
Publisher
Wiley
Published
2011-09
Volume
7
Issue
5
Pages
514-520
ISSN
  • 1552-5260 (ISSN-L)
  • 1552-5279
OpenAlex
W2158008198
Cited by
31
References
17
FWCI
2.36
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Impact of apolipoprotein ɛ4–cerebrospinal fluid beta‐amyloid interaction on hippocampal volume loss over 1 year in mild cognitive impairment. https://app.cochat.ai/papers/10.1016/j.jalz.2010.12.010
The paper
Chiang, G. C., Insel, P. S., Tosun, D., Schuff, N., Truran‐Sacrey, D., Raptentsetsang, S. T., Thompson, P. M., Reiman, E. M., Jack, C. R., Fox, N. C., Jagust, W. J., Harvey, D. J., Beckett, L. A., Gamst, A., Aisen, P. S., Petersen, R. C., & Weiner, M. W. (2011). Impact of apolipoprotein ɛ4–cerebrospinal fluid beta‐amyloid interaction on hippocampal volume loss over 1 year in mild cognitive impairment. Alzheimer's & Dementia. https://doi.org/10.1016/j.jalz.2010.12.010

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.